SUPPLEMENTARY MATERIAL

Clinical features of respiratory syncytial virus and influenza infections in hospitalized adults across three Italian regions

Tommaso Bigoni,¹ Franco Alfano,¹ Marta Vicentini,² Maria João Fonseca,³ Elisa Turriani,⁴ Elisa Vian,⁵ Micaela Romagnoli,⁶ Massimiliano Beccaria,⁷ Luca Pontalto,¹ Michele Schincaglia,¹ Federico Baraldi,¹ Alberto Papi¹

¹Respiratory Unit, Sant'Anna University Hospital, Ferrara, Italy; ²GlaxoSmithKline, Verona, Italy; ³GlaxoSmithKline, Lisbon, Portugal; ⁴GlaxoSmithKline, Wavre, Belgium; ⁵Microbiology Unit, Cà Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy; ⁶Respiratory Unit, Cà Foncello Hospital, AULSS2 Marca Trevigiana, Treviso, Italy; ⁷Respiratory Unit, ASST Mantua, Italy

Correspondence: Alberto Papi, Respiratory Unit, Sant'Anna University Hospital, Ferrara, Italy. Tel.: +39 0532 239752. E-mail: ppa@unife.it

Key words: respiratory syncytial virus, influenza virus, respiratory tract infections, hospitalization, comorbidity.



Methods. Definition of acute respiratory infection.

Acute respiratory infection was defined as the presence of:

• At least two respiratory symptoms/signs for at least 24 hours

OR

• At least one respiratory symptom/sign plus one systemic symptom/sign for at least 24 hours

Case definition			
Upper respiratory symptoms	Nasal congestion/rhinorrhea		
	Sore throat		
Lower respiratory symptoms	New or increased sputum		
	New or increased cough		
	New or increased dyspnea (shortness of breath)		
Lower respiratory signs	New or increased wheezing*		
	New or increased crackles (rales)/rhonchi, based on chest auscultation		
	Respiratory rate ≥20 respirations/minute**		
	Low or decreased oxygen saturation (<95% or ≤90% of baseline is <95%)**		
	Need for oxygen supplementation*		
Systemic signs and symptoms	Fever ¹ /feverishness ²		
	Fatigue		
	Body aches		
	Headache		
	Decreased appetite		

*Reported by study participant or investigator; **measured and reported by investigator only at admission. ¹Fever is defined as a temperature \geq 38.0°C by any route; ²feverishness is defined as the feeling of having fever without objective measurement.

Endpoint	Comparison	Group data	р
Age, years	Non-ARI vs. ARI	69.1 (13.6) <i>vs.</i> 64.2 (13.9)	0.003 ^a
	Non-infected vs. infected	67.3 (13.7) vs. 64.1 (14.9)	NS ^b
	Non-infected vs. viral infection	67.3 (13.7) <i>vs.</i> 58.5 (14.8)	NS ^a
	Non-infected vs. bacterial infection	67.3 (13.7) vs. 59.8 (16.9)	NS ^a
Radiologically confirmed pneumonia	Non-ARI vs. ARI	7 (5.4%) vs. 74 (65.5%)	0.000 ^c
	Non-infected vs. infected	54 (26.2%) vs. 27 (75.0%)	0.000 ^c
	Non-infected vs. viral infection	54 (26.2%) vs. 8 (66.7%)	0.003 ^c
	Non-infected vs. bacterial infection	54 (26.2%) vs. 11 (78.6%)	0.000 ^c
Charlson Comorbidity Index	Non-ARI vs. ARI	5.0 (3.1) vs. 3.5 (2.4)	< 0.001 ^a
	Non-infected vs. infected	4.4 (3.0) vs. 3.3 (2.4)	0.046 ^a
	Non-infected vs. viral infection	4.4 (3.0) vs. 2.6 (2.0)	NS ^a
	Non-infected vs. bacterial infection	4.4 (3.0) <i>vs.</i> 3.1 (2.8)	NS ^a
NIAID-OS	Non-ARI <i>vs.</i> ARI	4.3 (1.0) <i>vs.</i> 4.6 (1.0)	0.004 ^a
	Non-infected vs. infected	4.4 (1.0) <i>vs.</i> 4.9 (1.3)	0.010 ^b
	Non-infected vs. viral infection	4.4 (1.0) <i>vs.</i> 4.9 (1.4)	0.023 ^a
	Non-infected vs. bacterial infection	4.4 (1.0) <i>vs.</i> 5.2 (1.2)	0.009 ^a
Eosinophil count, cells/µL	Non-ARI <i>vs.</i> ARI	161.6 (217.5) vs. 109.6 (197.2)	0.001ª
	Non-infected vs. infected	152.7 (219.6) vs. 52.5 (107.6)	< 0.001 ^a
	Non-infected vs. viral infection	152.7 (219.6) vs. 7.5 (12.2)	<0.001 ^a
	Non-infected vs. bacterial infection	152.7 (219.6) vs. 60.7 (81.1)	NS ^a
Lymphocyte count, cells/µL	Non-ARI vs. ARI	3543.3 (20,448.2) vs. 1569.8 (2673.4)	0.003 ^a
	Non-infected vs. infected	2904.8 (16,391.0) vs. 1095.8 (537.0)	<0.001 ^a
	Non-infected vs. viral infection	2904.8 (16,391.0) vs. 790.8 (433.4)	<0.001 ^a
	Non-infected vs bacterial infection	2904 8 (16 391 0) vs 1234 3 (593 1)	NSa

Supplementary Table 1. Statistical comparisons of baseline characteristics.

Data are number (percent) or mean (standard deviation). ARI, acute respiratory infection (see supplement for definition); NS, not statistically significant; NIAID-OS, National Institute of Allergy and Infectious Disease Ordinal Scale (ranging from 0 [not hospitalised and with no limitation of activities] to 8 [death]). Statistical test applied: aWilcoxon; bt-test; cChi-square.

Note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries should be directed to the corresponding author for the article.



Endpoint	Comparison	Group data	р
Lower respiratory	Non-ARI <i>vs.</i> ARI	104 (78.2%) vs. 104 (92.0%)	0.003
signs or symptoms	Non-infected vs. infected	175 (83.3%) vs. 33 (91.7%)	NS
	Non-infected vs. viral infection	175 (83.3%) vs. 13 (100.0%)	NS
	Non-infected vs. bacterial infection	175 (83.3%) vs. 13 (92.9%)	NS
Systemic signs or	Non-ARI <i>vs.</i> ARI	30 (22.6%) vs. 77 (68.1%)	0.000
symptoms	Non-infected vs. infected	85 (40.5%) vs. 22 (61.1%)	0.021
	Non-infected vs. viral infection	85 (40.5%) vs. 10 (76.9%)	0.010
	Non-infected vs. bacterial infection	85 (40.5%) vs. 10 (71.4%)	0.023
Upper respiratory	Non-ARI <i>vs.</i> ARI	1 (0.8%) vs 10 (8.8%)	0.002
symptoms	Non-infected vs. infected	8 (3.8%) vs 3 (8.3%)	NS
	Non-infected vs. viral infection	8 (3.8%) vs 3 (23.1%)	0.002
	Non-infected vs. bacterial infection	8(3.8%) vs 0	NS

Supplementary Table 2. Statistical comparisons of acute respiratory infection symptoms.

Data are number (percent) positive for the symptoms category. ARI, acute respiratory infection (see supplement for definition); NS, not statistically significant. The statistical test applied was the Chi-square.

